Literature DB >> 20921252

Is bigger better? An argument for very low starting doses.

James P McCormack1, G Michael Allan, Adil S Virani.   

Abstract

Mesh：

Year:  2010        PMID： 20921252      PMCID： PMC3017255          DOI： 10.1503/cmaj.091481

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  26 in total

1.  Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events.

Authors:  J S Cohen
Journal:  Arch Intern Med       Date:  2001-04-09

2.  Lack of medication dose uniformity in commonly split tablets.

Authors:  Jaja Teng; Clara K Song; Roger L Williams; James E Polli
Journal:  J Am Pharm Assoc (Wash)       Date:  2002 Mar-Apr

3.  Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.

Authors:  James Cross; Howard Lee; Agnes Westelinck; Julie Nelson; Charles Grudzinskas; Carl Peck
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002-09       Impact factor: 2.890

4.  The potential of pill splitting to achieve cost savings.

Authors:  Randall S Stafford; David C Radley
Journal:  Am J Manag Care       Date:  2002-08       Impact factor: 2.229

5.  High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.

Authors:  Robert A Terkeltaub; Daniel E Furst; Katherine Bennett; Karin A Kook; R S Crockett; Matthew W Davis
Journal:  Arthritis Rheum       Date:  2010-04

6.  Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies.

Authors:  H E Bays; P B Moore; M A Drehobl; S Rosenblatt; P D Toth; C A Dujovne; R H Knopp; L J Lipka; A P Lebeaut; B Yang; L E Mellars; C Cuffie-Jackson; E P Veltri
Journal:  Clin Ther       Date:  2001-08       Impact factor: 3.393

7.  Efficacy of nonprescription doses of ibuprofen for treating migraine headache. a randomized controlled trial.

Authors:  J R Codispoti; M J Prior; M Fu; C M Harte; E B Nelson
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

8.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

Authors:  M Packer; P A Poole-Wilson; P W Armstrong; J G Cleland; J D Horowitz; B M Massie; L Rydén; K Thygesen; B F Uretsky
Journal:  Circulation       Date:  1999-12-07       Impact factor: 29.690

9.  Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.

Authors:  M D Ferrari; P J Goadsby; K I Roon; R B Lipton
Journal:  Cephalalgia       Date:  2002-10       Impact factor: 6.292

10.  The relative importance of physician communication, participatory decision making, and patient understanding in diabetes self-management.

Authors:  Michele Heisler; Reynard R Bouknight; Rodney A Hayward; Dylan M Smith; Eve A Kerr
Journal:  J Gen Intern Med       Date:  2002-04       Impact factor: 5.128
View more
  7 in total

1.  Lower drug dose may improve outcomes.

Authors:  Simon B Dimmitt
Journal:  CMAJ       Date:  2011-03-22       Impact factor: 8.262

2.  Shared decision making and high blood pressure.

Authors:  James McCormack
Journal:  Can Pharm J (Ott)       Date:  2018-04-02

3.  A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors.

Authors:  F Hieronymus; S Nilsson; E Eriksson
Journal:  Transl Psychiatry       Date:  2016-06-07       Impact factor: 6.222

4.  Low versus high dose of antimony for American cutaneous leishmaniasis: A randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil.

Authors:  Mauricio Naoto Saheki; Marcelo Rosandiski Lyra; Sandro Javier Bedoya-Pacheco; Liliane de Fátima Antônio; Maria Inês Fernandes Pimentel; Mariza de Matos Salgueiro; Érica de Camargo Ferreira E Vasconcellos; Sonia Regina Lambert Passos; Ginelza Peres Lima Dos Santos; Madelon Novato Ribeiro; Aline Fagundes; Maria de Fátima Madeira; Eliame Mouta-Confort; Mauro Célio de Almeida Marzochi; Cláudia Maria Valete-Rosalino; Armando de Oliveira Schubach
Journal:  PLoS One       Date:  2017-05-30       Impact factor: 3.240

5.  Lower-dose prescriptions in the post-marketing situation and the influencing factors thereon.

Authors:  Akiko Ogata; Masayuki Kaneko; Mamoru Narukawa
Journal:  PLoS One       Date:  2019-06-14       Impact factor: 3.240

6.  Ten Commandments for patient-centred treatment.

Authors:  Richard Lehman; Aaron M Tejani; James McCormack; Tom Perry; John S Yudkin
Journal:  Br J Gen Pract       Date:  2015-10       Impact factor: 5.386

7.  Isoliquiritigenin Derivatives Inhibit RANKL-Induced Osteoclastogenesis by Regulating p38 and NF-κB Activation in RAW 264.7 Cells.

Authors:  Seongtae Jeong; Seahyoung Lee; Kundo Kim; Yunmi Lee; Jiyun Lee; Sena Oh; Jung-Won Choi; Sang Woo Kim; Ki-Chul Hwang; Soyeon Lim
Journal:  Molecules       Date:  2020-08-27       Impact factor: 4.411
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.